The issue will allow the company to remain on track to exit its practice note 17 status by the first quarter of 2026.
PETALING JAYA: Pharmaniaga Bhd
has completed a rights issue and regularisation plan, allowing the company to remain on track to exit its practice note 17 or PN17 status by the first quarter of 2026.
In a statement, the company said a total of 3.46 billion renounceable rights shares were fully subscribed, with an oversubscription rate of 26.14%, reflecting strong support and confidence from existing shareholders.
